BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/10/2019 6:19:18 AM | Browse: 1007 | Download: 1006
 |
Received |
|
2019-02-14 06:25 |
 |
Peer-Review Started |
|
|
|
To Make the First Decision |
|
2019-03-08 01:11 |
|
Return for Revision |
|
2019-03-08 01:48 |
|
Revised |
|
2019-04-23 07:06 |
|
Second Decision |
|
2019-05-10 09:48 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-05-11 15:09 |
|
Articles in Press |
|
2019-05-11 15:09 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-06-05 23:54 |
|
Publish the Manuscript Online |
|
2019-06-10 06:19 |
| ISSN |
2220-3206 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights re-served. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Psychiatry |
| Manuscript Type |
Editorial |
| Article Title |
Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Rajesh R Tampi, Deena J Tampi, Juan J Young, Rakin A Hoq, Geetha Manikkara and Silpa Balachandran |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Rajesh R Tampi, MD, Chairman, Department of Psychiatry and Behavioral Sciences, Cleveland Clinic Akron General, Cleveland, NH, Ohio 44106, United States. rajesh.tampi@yale.edu |
| Key Words |
Pimavanserin; Systematic review; Parkinson’s disease; Parkinson’s disease psychosis; Psychosis; Antipsychotic |
| Core Tip |
Pimavanserin is an atypical antipsychotic that was the first medication to be approved by the Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). There are only two published tri-als that have evaluated the use of pimavanserin among individuals with PDP. Both studies are of good quality and found that pimavanserin improves psychotic symp-toms among individuals with PDP when compared to placebo. Additionally, pimavan-serin was fairly well tolerated in both studies and did not appear to cause significant sedation or worsen motor symptoms among individuals with PDP. |
| Publish Date |
2019-06-10 06:19 |
| Citation |
Tampi RR, Tampi DJ, Young JJ, Balachandran S, Hoq RA, Manikkara G. Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis. World J Psychiatr 2019; 9(3): 47-54 |
| URL |
https://www.wjgnet.com/2220-3206/full/v9/i3/47.htm |
| DOI |
https://dx.doi.org/10.5498/wjp.v9.i3.47 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
